Galectin-3 predicts cardiovascular events in patients with type-2 diabetes
ON DEMAND
Speaker:
Session title: Coronary Artery Disease (Chronic) ePosters
Topic: Coronary Artery Disease and Comorbidities
Session type: ePosters
Available from:

View abstract
Authors

A Lorenzo-Almoros1 , A Pello2 , A Acena2 , J Martinez-Milla2 , N Tarin3 , C Cristobal4 , LM Blanco-Colio5 , JL Martin-Ventura5 , A Huelmos6 , C Gutierrez-Landaluce4 , M Lopez-Castillo2 , J Alonso7 , J Egido8 , O Lorenzo5 , J Tunon2 , 1Fundacion Jimenez Diaz University Hospital, Internal Medicine - Madrid - Spain , 2Fundacion Jimenez Diaz University Hospital, Cardiology - Madrid - Spain , 3Hospital de Mostoles - Madrid - Spain , 4Hospital de Fuenlabrada, Cardiology - Madrid - Spain , 5Fundacion Jimenez Diaz University Hospital, Laboratory of Vascular Pathology, IIS - Madrid - Spain , 6Hospital de Alcorcon, Cardiology - madrid - Spain , 7Hospital de Getafe, Cardiology - madrid - Spain , 8Fundacion Jimenez Diaz University Hospital - Madrid - Spain ,

Abstract

Citation: N/A

Introduction:
Type-2 diabetes mellitus (T2DM) is associated with early and severe atherosclerosis. However, few biomarkers can predict cardiovascular events in this population.

Methods:
We followed 964 patients with coronary artery disease (CAD), assessing at baseline galectin-3, monocyte chemoattractant protein-1 (MCP-1) and N-terminal fragment of brain natriuretic peptide (NT-proBNP) plasma levels. Secondary outcomes were acute ischemia and heart failure or death. Primary outcome was the combination of the secondary outcomes.

Results:
Male patients were 75.0% in T2DM and 76.6% in the non-T2DM subgroup, (p=0.609). Age was 61.0 (54-72) and 60.0 (51-71) years, respectively (p=0.092). 232 patients had T2DM. Patients with T2DM showed higher MCP-1 [144 (113-195) vs. 133 (105-173) pg/ml, p=0.006] and galectin-3 [8.3 (6.5-10.5) vs. 7.8 (5.9-9.8) ng/ml, p=0.049] levels.

Median follow-up was 5.39 years (2.81- 6.92). Galectin-3 levels were associated with increased risk of the primary outcome in T2DM patients [HR 1.57 (1.07-2.30);p=0.022], along with a history of cerebrovascular events. Treatment with clopidogrel was associated with lower risk. In contrast, NT-proBNP and MCP-1, but not galectin-3, were related to increased risk of the event in non-diabetic patients [HR 1.21 (1.04-1.42);p=0.017 and HR 1.23 (1.05-1.44); p=0.012, respectively], along with male sex and age.

Galectin-3 was also the only biomarker that predicted the development of acute ischemic events and heart failure or death in T2DM patients, while in non-diabetics MCP-1 and NT-proBNP, respectively, predicted these events.

Conclusion:
In CAD patients, cardiovascular events are predicted by galectin-3 plasma levels in patients with T2DM, and by MCP-1 and NT-proBNP in those without T2DM.